Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
Gyre Therapeutics, Inc. (GYRE) had Operating Cash Flow per Share of $-0.04 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$105.76M |
|
$12.09M |
|
$3.88M |
|
$101.87M |
|
$89.59M |
|
$16.16M |
|
$7.05M |
|
$23.22M |
|
$23.22M |
|
$17.90M |
|
$17.90M |
|
$17.90M |
|
$17.90M |
|
$16.16M |
|
$17.75M |
|
85.09M |
|
102.29M |
|
$0.14 |
|
$0.05 |
|
| Balance Sheet Financials | |
$64.79M |
|
$23.88M |
|
$60.62M |
|
$125.41M |
|
$19.52M |
|
-- |
|
$7.49M |
|
$27.00M |
|
$98.40M |
|
$96.70M |
|
$98.40M |
|
86.31M |
|
| Cash Flow Statement Financials | |
$-3.64M |
|
$-19.88M |
|
$2.10M |
|
$33.51M |
|
$11.81M |
|
$-21.70M |
|
$0.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
96.33% |
|
15.28% |
|
15.28% |
|
16.78% |
|
21.95% |
|
11.43% |
|
$-5.55M |
|
-- |
|
-- |
|
-- |
|
0.84 |
|
0.61 |
|
4.27 |
|
85.52 |
|
18.19% |
|
18.51% |
|
14.27% |
|
18.19% |
|
$1.14 |
|
$-0.05 |
|
|
Operating Cash Flow per Share |
$-0.04 |